StockMacro
Menu

Zimmer Biomet

$101.10 +20% in 6 monthsMarket cap $19.1B

ZBH on XNYS, Health Care, Zimmer Biomet Holdings, Inc., job postings

Measures activity, not value. Not investment advice.

Profit fell 4.7% to $767.3M over 12 months while quarterly revenue grew 3.1%.

  • GoodFree cash flow of $1.6B over 12 months on $8.6B revenue

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The company has assembled a wide array of robotic platforms, and it spun out its dental and spine businesses in 2022.

Industry
Orthopedic, prosthetic & surgical appliances & supplies (Health Care)
Employees
17,000
Website
zimmerbiomet.com
Listed
NYSE, US
Last results
4 Nov 2026
Next results
expected around 9 Feb 2027 (an estimate: a year ago it reported on 10 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $2.1B, net income $191.6M.
Quarter to 31 Dec 2021: revenue $2.0B, net income -$84.0MQuarter to 31 Dec 2021: revenue $2.0B, net income -$84.0MQuarter to 31 Mar 2022: revenue $1.7B, net income $14.2MQuarter to 31 Mar 2022: revenue $1.7B, net income $14.2MQuarter to 30 Jun 2022: revenue $1.8B, net income $153.7MQuarter to 30 Jun 2022: revenue $1.8B, net income $153.7MQuarter to 30 Sep 2022: revenue $1.7B, net income $194.0MQuarter to 30 Sep 2022: revenue $1.7B, net income $194.0MQuarter to 31 Dec 2022: revenue –, net income -$130.5MQuarter to 31 Mar 2023: revenue $1.8B, net income $232.5MQuarter to 31 Mar 2023: revenue $1.8B, net income $232.5MQuarter to 30 Jun 2023: revenue $1.9B, net income $209.6MQuarter to 30 Jun 2023: revenue $1.9B, net income $209.6MQuarter to 30 Sep 2023: revenue $1.8B, net income $162.7MQuarter to 30 Sep 2023: revenue $1.8B, net income $162.7MQuarter to 31 Dec 2023: revenue –, net income $419.2MQuarter to 31 Mar 2024: revenue $1.9B, net income $172.4MQuarter to 31 Mar 2024: revenue $1.9B, net income $172.4MQuarter to 30 Jun 2024: revenue $1.9B, net income $242.8MQuarter to 30 Jun 2024: revenue $1.9B, net income $242.8MQuarter to 30 Sep 2024: revenue $1.8B, net income $249.1MQuarter to 30 Sep 2024: revenue $1.8B, net income $249.1MQuarter to 31 Dec 2024: revenue $2.0B, net income $239.5MQuarter to 31 Dec 2024: revenue $2.0B, net income $239.5MQuarter to 31 Mar 2025: revenue $1.9B, net income $182.0MQuarter to 31 Mar 2025: revenue $1.9B, net income $182.0MQuarter to 30 Jun 2025: revenue $2.1B, net income $152.8MQuarter to 30 Jun 2025: revenue $2.1B, net income $152.8MQuarter to 30 Sep 2025: revenue $2.0B, net income $230.9MQuarter to 30 Sep 2025: revenue $2.0B, net income $230.9MQuarter to 31 Dec 2025: revenue $2.2B, net income $139.3MQuarter to 31 Dec 2025: revenue $2.2B, net income $139.3MQuarter to 31 Mar 2026: revenue $2.1B, net income $238.1MQuarter to 31 Mar 2026: revenue $2.1B, net income $238.1MQuarter to 30 Jun 2026: revenue $2.2B, net income $198.3MQuarter to 30 Jun 2026: revenue $2.2B, net income $198.3MQuarter to 30 Sep 2026: revenue $2.1B, net income $191.6MQuarter to 30 Sep 2026: revenue $2.1B, net income $191.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $2.2B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$2.1B$191.6M
30 Jun 2026$2.2B$198.3M
31 Mar 2026$2.1B$238.1M
31 Dec 2025$2.2B$139.3M
30 Sep 2025$2.0B$230.9M
30 Jun 2025$2.1B$152.8M
31 Mar 2025$1.9B$182.0M
31 Dec 2024$2.0B$239.5M
30 Sep 2024$1.8B$249.1M
30 Jun 2024$1.9B$242.8M
31 Mar 2024$1.9B$172.4M
31 Dec 2023–$419.2M
30 Sep 2023$1.8B$162.7M
30 Jun 2023$1.9B$209.6M
31 Mar 2023$1.8B$232.5M
31 Dec 2022–-$130.5M
30 Sep 2022$1.7B$194.0M
30 Jun 2022$1.8B$153.7M
31 Mar 2022$1.7B$14.2M
31 Dec 2021$2.0B-$84.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $8.6B $8.0B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +7.0% +8.1%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $767.3M $805.2M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $3.96 $4.03
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 69.7% 71.4% 61.3%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 13.6% 16.6% 5.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 9.0% 10.1% -2.7%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 6.0% -20.0%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $1.6B $1.5B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $399.9M $1.3B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $7.5B $8.1B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $7.1B $6.8B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.59 0.22
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $67.19
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 24.9 27.5
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.2 2.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 3.1 3.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.5 3.4
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 0.95% 1.6%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Zimmer BiometZBH (this company) $19.1B24.92.2+7.0%9.0%
SterisSTE $24.8B30.04.0+8.1%13.4%
Align TechnologyALGN $10.9B22.22.6+4.6%11.7%
Mine SafetyMSA $6.5B21.63.3+8.1%15.0%
Edwards LifesciencesEW $58.6B57.38.8+13%15.3%
Intuitive SurgicalISRG $138.3B46.811.0+21%23.5%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$824K

bought $0, sold $824K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.7%

923 13F filers vs 890

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

98%

185.5M shares held by 13F filers (30 Sep 2026) of 189.3M outstanding (30 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.1%

7.8M shares sold short (30 Oct 2026) of 189.3M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.9

7.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-1.4%

8.0M shares sold short in the report before, 7.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

44%

44% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 59%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

418

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+3.1%

$2.1B vs $2.0B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+38%

$75.8M vs $55.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$14.0M

the 12 months before: $22.0M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$180K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

49

49 articles in the last 7 days; its usual week has 6.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

7.5×

49 articles in the last 7 days; its usual week has 6.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 102, 1.2× a year earlier

Price $101.10 on 20 Nov 2026, +14% over 12 months (12-month range $79.58 to $110.15)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $1.6M in the last 12 months (the 12 months before: -$754K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 13 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $2.1B in the latest quarter, +3.1% on a year earlier.
Capital spending per quarter. Capital spending $75.8M in the latest quarter, +38% on a year earlier.
Institutional holders (13F filers). 923 13F filers reported holding it in the latest 13F quarter, +1.0% on a year earlier.
Federal obligations. Federal obligations: $12.6M published in the last 12 months, -44% on the 12 months before.
Lobbying spend. Lobbying spend: $180K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 102 vs usual 75 (2026-09-30); 1.2x the same period a year earlier
8 Sep 20268-K and other filingsDirector or officer change
8 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Jun 20268-K and other filingsA major agreement ended
28 Apr 20268-K and other filingsDirector or officer change
28 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Jan 2026Sharp changeShort interest spike: short interest spike, 10.3M vs usual 7.1M (2025-12-31); 1.4x the same period a year earlier
12 Jan 20268-K and other filingsDirector or officer change
12 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Jun 20258-K and other filingsA major agreement ended
3 Jun 20258-K and other filingsDirector or officer change
27 May 20258-K and other filingsDirector or officer change
27 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Feb 20258-K and other filingsDirector or officer change
25 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Jul 20248-K and other filingsA major agreement ended
20 Jun 20248-K and other filingsDirector or officer change
15 May 20248-K and other filingsDirector or officer change
15 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Jan 20248-K and other filingsDirector or officer change
5 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Aug 2023Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 383K)
22 Aug 20238-K and other filingsDirector or officer change
22 Aug 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Jul 20238-K and other filingsA major agreement ended
15 Feb 20238-K and other filingsPrivate placement of securities (Form D)
22 Aug 20228-K and other filingsA major agreement ended
19 Jul 2022Lobbying filinglobbying engagement terminated (CAPITOL ASSOCIATES, INC.)
16 May 20228-K and other filingsDirector or officer change
16 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Mar 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 63.1M vs usual 29.1M (2021-12-31); 2.3x the same period a year earlier
1 Mar 20228-K and other filingsCompleted an acquisition or asset sale
Insider net buying (open market)
Month from 1 Dec 2021: -$348K published
Month from 1 Mar 2022: -$4.3M published
Month from 1 Jul 2022: -$56K published
Month from 1 Dec 2022: -$1.5M published
Month from 1 Mar 2023: -$2.9M published
Month from 1 Aug 2023: $616K published
Month from 1 Sep 2023: $237K published
Month from 1 Nov 2023: $224K published
Month from 1 Feb 2024: -$3.4M published
Month from 1 Mar 2024: -$216K published
Month from 1 Jun 2024: -$1.5M published
Month from 1 Mar 2025: -$151K published
Month from 1 Jun 2025: -$169K published
Month from 1 Aug 2025: -$154K published
Month from 1 Sep 2025: -$281K published
Month from 1 Feb 2026: -$96K published
Month from 1 Mar 2026: -$251K published
Month from 1 Jun 2026: -$413K published
Month from 1 Sep 2026: -$824K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 13 published
Revenue per quarter
Quarter ended 31 Dec 2021: $2.0B, -2.3% on a year earlier; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $1.7B, -10% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $1.8B, -12% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $1.7B, -13% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Mar 2023: $1.8B, +10% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $1.9B, +4.9% on a year earlier; public on 2 Aug 2023
Quarter ended 30 Sep 2023: $1.8B, +5.0% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Mar 2024: $1.9B, +3.2% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $1.9B, +3.9% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $1.8B, +4.0% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $2.0B; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $1.9B, +1.1% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $2.1B, +7.0% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $2.0B, +9.7% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $2.2B, +11% on a year earlier; public on 21 Feb 2026
Quarter ended 31 Mar 2026: $2.1B, +9.3% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $2.2B, +4.8% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $2.1B, +3.1% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $63.1M, +128% on a year earlier; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $36.4M, +33% on a year earlier; public on 6 May 2022
Quarter ended 31 Mar 2023: $46.7M, +28% on a year earlier; public on 3 May 2023
Quarter ended 30 Jun 2023: $97.3M; public on 2 Aug 2023
Quarter ended 30 Sep 2023: $84.3M; public on 8 Nov 2023
Quarter ended 31 Mar 2024: $55.1M, +18% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $52.7M, -46% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $44.5M, -47% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $51.5M; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $44.6M, -19% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $50.1M, -4.9% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $55.0M, +24% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $74.8M, +45% on a year earlier; public on 21 Feb 2026
Quarter ended 31 Mar 2026: $36.3M, -19% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $54.2M, +8.2% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $75.8M, +38% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 889; public on 14 Feb 2022
31 Mar 2022 report: 907; public on 16 May 2022
30 Jun 2022 report: 890; public on 15 Aug 2022
30 Sep 2022 report: 836; public on 14 Nov 2022
31 Dec 2022 report: 885; public on 14 Feb 2023
31 Mar 2023 report: 923; public on 15 May 2023
30 Jun 2023 report: 950; public on 14 Aug 2023
30 Sep 2023 report: 924; public on 14 Nov 2023
31 Dec 2023 report: 953; public on 14 Feb 2024
31 Mar 2024 report: 956; public on 15 May 2024
30 Jun 2024 report: 955; public on 14 Aug 2024
30 Sep 2024 report: 921; public on 14 Nov 2024
31 Dec 2024 report: 972; public on 14 Feb 2025
31 Mar 2025 report: 954; public on 15 May 2025
30 Jun 2025 report: 894; public on 14 Aug 2025
30 Sep 2025 report: 914; public on 14 Nov 2025
31 Dec 2025 report: 905; public on 17 Feb 2026
31 Mar 2026 report: 889; public on 15 May 2026
30 Jun 2026 report: 890; public on 14 Aug 2026
30 Sep 2026 report: 923; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $674K published
Month from 1 Dec 2021: $4.5M published
Month from 1 Jan 2022: $2.1M published
Month from 1 Feb 2022: $2.0M published
Month from 1 Mar 2022: $2.6M published
Month from 1 Apr 2022: $1.6M published
Month from 1 May 2022: $2.2M published
Month from 1 Jun 2022: $2.5M published
Month from 1 Jul 2022: $2.8M published
Month from 1 Aug 2022: $2.5M published
Month from 1 Sep 2022: $2.9M published
Month from 1 Oct 2022: $2.1M published
Month from 1 Nov 2022: $3.2M published
Month from 1 Dec 2022: $5.3M published
Month from 1 Jan 2023: $1.8M published
Month from 1 Feb 2023: $1.6M published
Month from 1 Mar 2023: $1.9M published
Month from 1 Apr 2023: $3.1M published
Month from 1 May 2023: $3.3M published
Month from 1 Jun 2023: $3.7M published
Month from 1 Jul 2023: $2.3M published
Month from 1 Aug 2023: $2.3M published
Month from 1 Sep 2023: $3.7M published
Month from 1 Oct 2023: $2.7M published
Month from 1 Nov 2023: $4.9M published
Month from 1 Dec 2023: $4.2M published
Month from 1 Jan 2024: $1.3M published
Month from 1 Feb 2024: $1.9M published
Month from 1 Mar 2024: $2.4M published
Month from 1 Apr 2024: $1.9M published
Month from 1 May 2024: $2.4M published
Month from 1 Jun 2024: $2.1M published
Month from 1 Jul 2024: $1.9M published
Month from 1 Aug 2024: $1.8M published
Month from 1 Sep 2024: $1.8M published
Month from 1 Oct 2024: $2.1M published
Month from 1 Nov 2024: $2.0M published
Month from 1 Dec 2024: $1.2M published
Month from 1 Jan 2025: $1.7M published
Month from 1 Feb 2025: $1.4M published
Month from 1 Mar 2025: $2.0M published
Month from 1 Apr 2025: $1.5M published
Month from 1 May 2025: $2.0M published
Month from 1 Jun 2025: $1.6M published
Month from 1 Jul 2025: $1.7M published
Month from 1 Aug 2025: $1.8M published
Month from 1 Sep 2025: $2.8M published
Month from 1 Oct 2025: $2.2M published
Month from 1 Nov 2025: $2.5M published
Month from 1 Dec 2025: $1.7M published
Month from 1 Jan 2026: $598K published
Month from 1 Feb 2026: $2.0M published
Month from 1 Mar 2026: $2.1M published
Month from 1 Apr 2026: $1.8M published
Month from 1 May 2026: $1.8M published
Month from 1 Jun 2026: $1.5M published
Month from 1 Jul 2026: $72K published
Month from 1 Aug 2026: $697K published
Month from 1 Sep 2026: $721 published
Month from 1 Oct 2026: $112K published
Month from 1 Nov 2026: $312K published
Lobbying spend
Quarter from 1 Jan 2022: $140K published
Quarter from 1 Apr 2022: $90K published
Quarter from 1 Jul 2022: $110K published
Quarter from 1 Oct 2026: $180K published

What is unusual now

  • Made public in the last 90 days: it saw 102 13F filers open a new position in the quarter ended 30 Sep 2026, 1.2× the same quarter last year.
  • Many funds opening a new position: saw 102 13F filers open a new position in the quarter ended 30 Sep 2026, 1.2× the same quarter last year Public on 16 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $1.6M in the last 12 months (the 12 months before: -$754K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 13 published in the last 12 months (none in the 12 months before).

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 83 insider trades

Last 90 days: 2 sales, $824K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
15 Sep 2026Kevin R ThornalGrp Pres-Global BusinessSell5,691$92.95$529KForm 4
9 Sep 2026Chad F PhippsSee remarks below.Sell3,000$98.35$295KForm 4
2 Jun 2026Sang YiGroup President, Asia PacificSell5,000$82.64$413KForm 4
16 Mar 2026Lori WinklerSVP and CHROSell2,650$94.66$251KForm 4
17 Feb 2026Sang YiGroup President, Asia PacificSell1,000$96.49$96KForm 4
15 Sep 2025Sang YiGroup President, Asia PacificSell1,200$103.59$124KForm 4
10 Sep 2025Lori WinklerSVP and CHROSell1,500$104.15$156KForm 4
20 Aug 2025Lori WinklerSVP and CHROSell1,500$102.49$154KForm 4

923 institutions reported shares at the end of Q3 2026, 98% of the shares outstanding; 101 opened a position, 67 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Dodge & Cox22.7M12.0%$2.0B-1.4M-5.8%
BlackRock, Inc.15.6M8.25%$1.4B-2,4510%
Vanguard Capital Management LLC12.5M6.59%$1.1B-155K-1.2%
Harris Associates L P12.2M6.46%$1.1B-508K-4.0%
Capital International Investors10.9M5.74%$964.6M-1.3M-11%
State Street Corp8.9M4.69%$791.2M+6,280+0.1%
Vanguard Portfolio Management LLC8.1M4.30%$723.1M-302K-3.6%
Geode Capital Management, LLC5.4M2.85%$476.7M+38K+0.7%
Invesco Ltd.4.1M2.18%$366.8M+149K+3.7%
Primecap Management Co3.8M2.01%$337.7M-15K-0.4%

Federal contracts

All 7 federal contracts

No new award in 12 months; the latest was signed 25 Aug 2023. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
25 Aug 2023Department of Veterans Affairs$1.0MZIMMER BIOMED KITSUSAspending
10 May 2011Department of Veterans AffairsEXPRESS REPORT FOR MEDICAL SUPPLIES AND IMPLANTS FOR VA MEDICAL CENTER, MILWAUKEE, WIUSAspending
1 Oct 2010Department of Veterans AffairsEXPRESS REPORT OF PROSTHETIC ORDERS TO ZIMMER FOR FY 2011, OCTOBER THROUGH AUGUST; 157 TOTAL ORDERSUSAspending
3 Oct 2007Department of Veterans AffairsPROSTHETICS EXPRESS REPORT FY 08USAspending
2 Oct 2007Department of Veterans AffairsPROSTHETICS EXPRESS REPORT FY 08USAspending
1 Oct 2007Department of Veterans AffairsPROSTHETICS EXPRESS REPORT FY 08USAspending
1 Oct 2007Department of Veterans AffairsPROSTHETICS EXPRESS REPORT FY 08USAspending

Company events

All 77 company events

In 12 months: 3 director or officer changes, 2 major agreements, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
12 Nov 2026Underwriting agreements for €500M 4.375% notes due 2033 and $500M 5.850% notes due 2036; issuance completed Nov 12, 2026Same filing: took on new debt8-K
8 Sep 2026Director or officer change8-K
29 Jun 2026Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
28 Apr 2026Director or officer change8-K
12 Jan 2026Director or officer change8-K
30 Jun 2025Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
3 Jun 2025Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K
27 May 2025Director or officer change8-K

418 open postings; careers site tracked since 21 Nov 2026. Most in Sales & business development 29%, Manufacturing & production 20%, Supply chain & procurement 11%, Research & science 5%.

PostedJobLocation
21 Nov 2026Sr Supply Chain PlannerSupply chain & procurementEnglewood, Colorado, United States
20 Nov 2026Field Services Engineer IField service & installationWashington D.C., District of Columbia, United States; Baltimore, Maryland, United States
20 Nov 2026Field Services Engineer IField service & installationNew York City, New York, United States
20 Nov 2026Cell Support OperatorManufacturing & productionWarsaw, Indiana, United States
20 Nov 2026Mitarbeiter (m/w/d) Kit Building & RetourenSupply chain & procurementEschbach, Baden-Württemberg, Germany
20 Nov 2026Field Services Engineer IField service & installationChicago, Illinois, United States
20 Nov 2026Program Development Assoc ManagerSales & business developmentSalt Lake City, Utah, United States
20 Nov 2026Field Services Engineer IField service & installationAustin, Texas, United States; Houston, Texas, United States; Dallas, Texas, United States

Reported lobbying spend: $180K in Q3 2026, $110K in Q2 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Apr 2022EndedCapitol Associates, Inc.for Zimmer Biomet, Inc.Issues impacting health equity and health disparities, particularly regarding musculoskeletal health and COVID-19. CMMI alternative payment models and exacerbation of health disparities; COVID-19 Relief. Issues regarding health equity and eliminating health disparities. Improving Alternative Payment Models to address health disparities.Health issues, Medicare/MedicaidFiling
31 Dec 2020EndedG2G Consultingfor Embodyregarding repairing injuries in the militaryHealth issues, BudgetFiling
29 Jul 2019NewZimmer Biomet, Inc.its own lobbyistsTrade, Manufacturing, Taxation, Health issues, Medicare/Medicaid, MED, TORFiling
2 Jan 2018NewG2G Consultingfor Embodyeducate on ligament and tendon injuries, and fundingHealth issuesFiling
31 Mar 2017EndedJeffrey J. Kimbell & Associates, Inc.for Zimmer, Inc.Issues related to medical device and regulatory policyHealth issuesFiling
31 Mar 2017EndedLne Groupfor ZimmerNot statedFiling
1 Feb 2017NewJeffrey J. Kimbell & Associates, Inc.for Zimmer, Inc.Issues related to health careHealth issuesFiling
13 May 2016NewCapitol Associates, Inc.for Zimmer Biomet, Inc.Health disparitiesHealth issues, Medicare/MedicaidFiling

The 5 newest of 450 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 16 Nov 2026Institutional holdings change

    saw 102 13F filers open a new position in the quarter ended 30 Sep 2026, 1.2× the same quarter last year.

    Same quarter last year: 87; its normal quarter is 75.

    See the evidence
    This period
    102 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    75
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +3.6
    Same quarter last year
    87
    History used
    4,748 days
    2024-09-30: 672024-12-31: 782025-03-31: 652025-06-30: 752025-09-30: 872025-12-31: 752026-03-31: 722026-06-30: 802026-09-30: 102
    the quarter ended 30 Sep 20268 earlier quartersnormal: 75

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 8 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 8 Sep 2026Filings record

    Director or officer change

  4. 29 Jun 2026Filings record

    A major agreement ended

  5. 28 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 28 Apr 2026Filings record

    Director or officer change

  7. 13 Jan 2026Short interest and volume change

    had 10.3M shares sold short in the 31 Dec 2025 report, 1.4× the same report last year.

    Same report last year: 7.3M; its normal report is 7.1M.

    See the evidence
    This period
    10.3M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    7.1M
    Typical spread (median absolute deviation)
    530K
    How far from its usual level
    +4.2
    Same report last year
    7.3M
    History used
    2,924 days
    2024-12-31: 7.3M2025-01-15: 7.6M2025-01-31: 7.4M2025-02-14: 7.1M2025-02-28: 7.1M2025-03-14: 6.2M2025-03-31: 7.2M2025-04-15: 6.3M2025-04-30: 6.3M2025-05-15: 6.0M2025-05-30: 5.5M2025-06-13: 6.4M2025-06-30: 8.4M2025-07-15: 7.3M2025-07-31: 5.9M2025-08-15: 7.0M2025-08-29: 5.8M2025-09-15: 6.6M2025-09-30: 6.8M2025-10-15: 7.1M2025-10-31: 7.3M2025-11-14: 7.5M2025-11-28: 8.5M2025-12-15: 7.8M2025-12-31: 10.3M
    the 31 Dec 2025 report24 earlier reportsnormal: 7.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 12 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 12 Jan 2026Filings record

    Director or officer change

  10. 14 Aug 2025Institutional holdings record

    HARRIS ASSOCIATES L P opened a $340.0M position (2025Q2 13F)

  11. 13 Aug 2025Institutional holdings record

    Capital International Investors opened a $618.0M position (2025Q2 13F)

  12. 30 Jun 2025Filings record

    A major agreement ended

  13. 3 Jun 2025Filings record

    Director or officer change

  14. 27 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 27 May 2025Filings record

    Director or officer change

  16. 25 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 25 Feb 2025Filings record

    Director or officer change

  18. 1 Jul 2024Filings record

    A major agreement ended

  19. 20 Jun 2024Filings record

    Director or officer change

  20. 15 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 15 May 2024Filings record

    Director or officer change

  22. 5 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 5 Jan 2024Filings record

    Director or officer change

  24. 14 Nov 2023Insiders record

    Jafry Syed A. (director) bought 2,135 shares of ZBH ($223,641) (dated 13 Nov 2023)

  25. 30 Sep 2023Insiders record

    BEGLEY CHRISTOPHER B (director) bought 1,000 shares of ZBH ($117,110) (dated 29 Sep 2023)

  26. 2 Sep 2023Insiders record

    Kolli Sreelakshmi (director) bought 1,000 shares of ZBH ($120,370) (dated 1 Sep 2023)

  27. 31 Aug 2023Insiders record

    HAGEMANN ROBERT (director) bought 2,000 shares of ZBH ($232,960) (dated 30 Aug 2023)

  28. 31 Aug 2023Government contracts record

    ZIMMER US INC: new Department of Veterans Affairs contract 36C25623P1502 ($1.1M) (dated 25 Aug 2023)

  29. 30 Aug 2023Insiders change

    had 3 insiders buy $383K of its shares on the open market within 30 days (3 filings).

    Who bought: Higgins Arthur J, Michelson Michael W, Bernard Betsy J.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $383K
    Window
    31 Jul 2023 to 30 Aug 2023

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  30. 30 Aug 2023Insiders record

    BERNARD BETSY J (director) bought 1,021 shares of ZBH ($116,809) (dated 29 Aug 2023)

  31. 30 Aug 2023Insiders record

    MICHELSON MICHAEL W (director) bought 1,300 shares of ZBH ($150,150) (dated 29 Aug 2023)

  32. 26 Aug 2023Insiders record

    HIGGINS ARTHUR J (director) bought 1,000 shares of ZBH ($115,615) (dated 25 Aug 2023)

  33. 22 Aug 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 22 Aug 2023Filings record

    Director or officer change

  35. 10 Jul 2023Filings record

    A major agreement ended

  36. 15 Feb 2023Filings record

    Private placement of securities (Form D)

  37. 22 Aug 2022Filings record

    A major agreement ended

  38. 19 Jul 2022Lobbying record

    ZIMMER BIOMET, INC.: lobbying engagement terminated (CAPITOL ASSOCIATES, INC.) (dated 30 Apr 2022)

  39. 16 May 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 16 May 2022Filings record

    Director or officer change

Showing the newest 40 of 114 entries; narrow the window or the kind of data to see older ones.

Not listed: 220 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001136869
Ticker
ZBH
Domain
zimmerbiomet.com
Employer name
Biomet Manufacturing, LLC (formerly Corp.), CD Diagnostics Inc., zimmer biomet cmf and thoracic, Zimmer Biomet Holdings, Inc. and 3 more (7 unverified)
Fein
35-2074039, 45-4131234, 61-1414494, 81-0550216 and 1 more (5 unverified)
Hq location
IN|WARSAW|46580 (1 unverified)
Lobbying client
biomet, zimmer, zimmer biomet
Name
3-102-910623 Sociedad de Responsabilidad Limitada, A&E Medical Corp, Alto Development Corp, Avitus Orthopaedics, Inc and 169 more
Uei
DMQCTMPMH684, U9BBMTXTPXY8, WNMZS4L9EJ73
Wikidata
Q203552
Wikipedia
Zimmer Biomet
  • DOL H-1B labor condition applications and PERM certifications63 data points27 Apr 2020 to 21 Sep 2026
  • Federal lobbying disclosures (LDA)16 records, 193 data points30 Jun 2005 to 30 Sep 2026
  • SEC Form 13F institutional holdings8 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)200 records7 Jan 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1312 data points31 Dec 2006 to 30 Oct 2026
  • SEC Form 4 insider transactions83 records, 284 data points12 Jan 2016 to 15 Sep 2026
  • FINRA short interest (twice monthly)627 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards7 records, 16164 data points1 Oct 2007 to 27 Oct 2026
  • Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026